CD86 and cancer: Based on the cellular composition in TLSs, a 12-chemokine signature (CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11, CXCL13) and 9 gene signature (CCL19, CCL21, CXCL13, CCR7, SELL, LAMP3, CXCR4, CD86, BCL6) were proposed with the conclusion that this signature showed an extremely heterogeneous distribution among different cancer types [13, 14].